|
|
|
|
|
|
|
|
|
11.03.26 - 13:03
|
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the selection of Cincinnati Children's Applied Gene and Cell Therapy Center (“AGCTC”) as the lead contract development and manufacturing partner to conduct the formal technology transfer of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma (“rrMM”)....
|
|
|
|
|
04.02.26 - 22:51
|
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic assets, today announced the closing of a previously announced transaction pursuant to which Tempest acquired certain dual-targeting chimeric antigen receptor (CAR)-T programs and obtained financing support from Factor Bioscience Inc. and its affiliates (collectively, “Factor”) in an all-stock transaction resulting in a diverse portfolio including clinical-stage product candidates and an extended runway with multiple potential near-term milestones (the “Transaction”)....
|
|
|
|
|
20.01.26 - 23:24
|
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the “Record Date”) for the distribution of warrants to purchase Tempest common stock (“Warrants”) as a dividend (the “Warrant Dividends”), as contemplated by Tempest's previously announced Asset Purchase Agreement (the “Asset Purchase Agreement”) with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of closing conditions for the transactions contemplated by the Asset Purchase Agreement (the “Closing Conditions”), including receipt of stockholder approval of Proposal 5 contained in Tempest's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on Decem...
|
|
|
|
|
|
|
|
|
19.11.25 - 15:03
|
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- In a transaction designed to both expand its pipeline and extend its runway, Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “the Company”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into definitive agreements to acquire certain dual-targeting chimeric antigen receptor (CAR)-T programs from Factor Bioscience Inc. and its affiliates (collectively, “Factor”) in an all-stock transaction (the “Proposed Transaction”). The Proposed Transaction is expected to close in early 2026, subject to necessary stockholder approvals and satisfaction of closing conditions (the “Closing”)....
|
|
|
|
|
13.08.25 - 14:03
|
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer (Business Wire)
|
|
|
Dr. Whiting brings extensive experience in medical oncology spanning patient care, early drug discovery, and late-stage global development activities
His leadership will deepen the company's clinical expertise to support progress of its portfolio of innovative investigational therapies for cancers and immune disorders
Dr. Whiting joins from Tempest Therapeutics where he orchestrated successful clinical trials of multiple investigative small molecules for cancer
SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the appointment of Sam Whiting, M.D., Ph.D., as Chief Medical Officer. Dr. Whiting is an accomplished medical oncologist who brings to Vividion more than two decades of experience spanning patient care, early drug discovery, and late-stage global clinical development. Vividion utilizes innovative discovery technologies to unlock difficult-to-drug target...
|
|
|
|
|
|
|
30.06.25 - 14:03
|
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC)....
|
|
|
11.06.25 - 14:03
|
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock (GlobeNewswire EN)
|
|
|
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale in a registered direct offering of 739,000 shares of its common stock (or common stock equivalents), at an offering price of $6.25 per share of common stock (or common stock equivalent). The closing of the offering is expected to occur on or about June 12, 2025, subject to the satisfaction of customary closing conditions....
|
|
|
09.04.25 - 09:54
|
XFRA: 3OS0: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
TEMPEST THERAP.NEW O.N. 3OS0 US87978U2078 BAW/UFN...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
